|
FY2026
12 months to Jun 30, 2026
|
FY2025
12 months to Jun 30, 2025
|
|
|---|---|---|
| Revenue from contracts with customers | ||
| Cost of sales | ||
| Gross Profit | ||
| Other income | ||
| Other losses | ||
| General and administrative expenses | ||
| Research and development expenses | ||
| Share-based payments expenses | ||
| Gain/(loss) on movement in contingent consideration | ||
| Operating loss | ||
| Finance expenses | ||
| Loss before income tax | ||
| Income tax expense | ||
| Loss for the year | ||
| Other comprehensive income/(loss) | ||
| Exchange differences on translation of foreign operations | ||
| Total comprehensive loss for the year | ||
| Loss per share for loss attributable to the ordinary equity holders of the group: | ||
| Basic loss per share (in Dollars per share) | ||
| Diluted loss per share (in Dollars per share) | ||
| Total comprehensive loss for the year is attributable to: | ||
| Owners of Radiopharm Theranostics Limited | ||
| Non-controlling interests |
Loading...
